NSE: ZYDUSLIFE | BSE: 532321

Mid-range Performer

Download real time

934.55 -1.20 (-0.13%)

622.4K NSE+BSE Volume

NSE 05 Dec, 2025 1:57 PM (IST)

94,037.6

Market Cap

High in industry

Beta 1Year

Low volatility

Zydus Lifesciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ZYDUSLIFE, BSE:532321 Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd.

04 Feb 2022, 12:00AM

934.55

-0.13%

Cadila Healthcare Limited

Hold: Zydus Lifesciences Ltd.

Target

ICICI Securities Limited

In the last two years, KNL has increased its total paint manufacturing capacity by 28% to 5.3 lakh tonnes at an investment of ~| 1100 crore Q3FY22 Results: Lower industrial volume offtake and delay in passing of higher...

Zydus Lifesciences L.. has an average target of 1040.50 from 4 brokers.

Zydus Lifesciences Ltd.

01 Nov 2021

934.55

-0.13%

Cadila Healthcare Limited

Hold: Zydus Lifesciences Ltd.

Target

ICICI Securities Limited

Number of FII/FPI investors increased from 697 to 707 in Sep 2025 qtr.

Zydus Lifesciences Ltd.

24 Aug 2021

934.55

-0.13%

Event Update - ZyCoV-D vaccine approved in increasingly competitive domestic market - BUY

Buy: Zydus Lifesciences Ltd.

Prabhudas Lilladhar

trial of the vaccine on 28,000 volunteers, including 1400 subjects in the age group of 12-17 age group. With favorable and acceptable safety profile, the approval was unique as it allows ZyCoV-D to be administered (first time in India) with adolescent age group (12-17 yrs) along with adult population (18 yrs and above). CDH also applied for 2-dose vaccine which may take another 1-2 months for expert group of DCGI to evaluate its efficacy profile data. Thermo-stability (2-8degree temp. for storage) of the vaccine helps in easing storage and transportation costs. Stock filling of the vaccine and commercial...

Zydus Lifesciences Ltd. is trading below all available SMAs

Zydus Lifesciences Ltd.

19 Aug 2021

934.55

-0.13%

CADILA HEALTH CARE LIMITED

Buy: Zydus Lifesciences Ltd.

Target

Geojit BNP Paribas

Cadila Healthcare is India's leading vertically integrated pharmaceutical company. With its presence across the value chain, it manufactures finished dosage forms, active pharmaceutical ingredients, animal healthcare...

Zydus Lifesciences L.. has an average target of 1040.50 from 4 brokers.

Zydus Lifesciences Ltd.

13 Aug 2021

934.55

-0.13%

Q1FY22 Result Update - India formulation outperformed, US bottoms out; Upgrade to BUY

Buy: Zydus Lifesciences Ltd.

Recommendation Target

Prabhudas Lilladhar

We maintain our earnings estimates for FY23E and decrease FY22E following 12% lower estimates on US generics in the quarter, as all Indian peers currently witnessed headwinds due to strong competition and price erosion....

Zydus Lifesciences L.. has an average target of 1040.50 from 4 brokers.

Zydus Lifesciences Ltd.

12 Aug 2021

934.55

-0.13%

Cadila Healthcare Limited

Hold: Zydus Lifesciences Ltd.

Target

ICICI Securities Limited

It has a global presence and sells its products in the US, India, Europe & emerging markets including countries in LatAm, Asia Pacific & Africa Cadila is the fourth largest pharma company in India with 14 brands among...

Number of FII/FPI investors increased from 697 to 707 in Sep 2025 qtr.

Zydus Lifesciences Ltd.

02 Jun 2021

934.55

-0.13%

CADILA HEALTH CARE LIMITED

Buy: Zydus Lifesciences Ltd.

Recommendation Target

Geojit BNP Paribas

Number of FII/FPI investors increased from 697 to 707 in Sep 2025 qtr.

Zydus Lifesciences Ltd.

28 May 2021

934.55

-0.13%

Cadila Healthcare Limited

Hold: Zydus Lifesciences Ltd.

Recommendation Target

ICICI Securities Limited

Q4 revenues were in-line with I-direct estimates whereas profitability was higher due to lower-than-expected other expenditure and DTA related adjustments. On the US front, Cadila plans to venture into complex injectables, which is likely to provide meaningful traction from FY23-24 onwards. The wellness segment performance hinges upon Cadila's marketing & distribution prowess besides effective product positioning. India formulations business, after recent restructuring, is likely to stabilise. The company has significantly improved net debt position in FY21 (nearly...

Number of FII/FPI investors increased from 697 to 707 in Sep 2025 qtr.

Zydus Lifesciences Ltd.

28 May 2021

934.55

-0.13%

India sales/operating leverage drives earnings

Buy: Zydus Lifesciences Ltd.

Target

Motilal Oswal

CDH delivered in line 4QFY21 earnings. Healthy traction in the Domestic Formulation (DF) and Consumer Wellness has offset the impact of weak US sales and improved EBITDA margin. It is well-placed to benefit from preventive as well as treatment drugs for COVID-19, in addition to improving performance in its core DF portfolio. The innovative pipeline is also progressing well in clinical studies. We maintain our FY22E/FY23E EPS estimate. We continue to value CDH at 25x 12-month forward earnings to arrive at our TP of INR740. We remain...

Zydus Lifesciences Ltd. is trading below all available SMAs

Zydus Lifesciences Ltd.

28 May 2021

934.55

-0.13%

Q4FY21 Result Update - Growth in India offsets fall in US - Downgrade to 'Accumulate'

Accumulate: Zydus Lifesciences Ltd.

Target

Prabhudas Lilladhar

We revise upgrade our earnings estimate by 22% in FY23E while marginally decreased by 2.4% in FY22E as we increase estimates of Consumer healthcare, India formulations (with 40+ launches) and EU sales while removing animal healthcare sales from 2HFY22 due to sale of business. The 4QFY21 sales were in-line, while earnings beat our estimates with...

Number of FII/FPI investors increased from 697 to 707 in Sep 2025 qtr.

Is Cadila Healthcare Ltd. worth buying?

864 Votes:

Buy 81.94%

Sell 9.95%

Hold 8.1%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf